Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Progress in Neuro-psychopharmacology and Biological Psychiatry

• Publication date

  2014-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pnpbp.2014.04.006PMID 24747871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.

  2012cited by this paper
• Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.

  2012cited by this paper
• Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine.

  2012cited by this paper
• Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.

  2011cited by this paper
• Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats

  2011cited by this paper
• Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids

  2010cited by this paper
• Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

  2010cited by this paper
• Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.

  2010cited by this paper
• Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice.

  2010cited by this paper
• Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

  2009cited by this paper
• Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol

  2008cited by this paper
• Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.

  2008cited by this paper
• Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

  2007cited by this paper
• Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.

  2007influential reference
• Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

  2007cited by this paper
• Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior.

  2007cited by this paper
• Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats

  2007influential reference
• Antischizophrenic Drugs : Chronic Treatment Elevates Dopamine Receptor Binding in Brain

  2006cited by this paper
• High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats.

  2005cited by this paper
• A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

  2005cited by this paper
• An experimental model of tardive dyskinesia

  2005cited by this paper
• Distribution of cannabinoid receptors in the central and peripheral nervous system.

  2005cited by this paper
• Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis

  2005cited by this paper
• Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.

  2004cited by this paper
• Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.

  2004cited by this paper
• D2 Dopamine Receptors Modulate Gα-Subunit Coupling of the CB1 Cannabinoid Receptor

  2004cited by this paper
• Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

  2003cited by this paper
• Oxidative Mechanisms and Tardive Dyskinesia

  2003cited by this paper
• Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.

  2003cited by this paper
• Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia.

  2003cited by this paper
• Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.

  2003cited by this paper
• Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's disease

  2003cited by this paper
• Postsynaptic endocannabinoid release is critical to long-term depression in the striatum

  2002cited by this paper
• Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

  2000cited by this paper
• Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?

  2000cited by this paper
• Reversal of Dopamine D2 Receptor Responses by an Anandamide Transport Inhibitor

  2000cited by this paper
• The endocannabinoid system as a target for therapeutic drugs.

  2000cited by this paper
• Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice

  2000cited by this paper
• Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.

  2000cited by this paper
• Anandamide: a candidate neurotransmitter heads for the big leagues

  1999cited by this paper
• Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

  1999influential reference
• Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.

  1998cited by this paper
• Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.

  1998cited by this paper
• Effects of intrapallidal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system

  1998cited by this paper
• Effects of intrastriatal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system

  1998cited by this paper
• Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

  1998cited by this paper
• The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.

  1997cited by this paper
• Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor

  1997cited by this paper
• Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system.

  1996influential reference
• Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol

  1996cited by this paper
• The treatment of tardive dyskinesia.

  1996cited by this paper
• Antipsychotic-Induced Tardive Dyskinesia

  1995cited by this paper
• Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.

  1994cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

  1992cited by this paper
• Oxygen radicals and neuropsychiatric illness. Some speculations.

  1991cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice.

  1990cited by this paper
• Treatment of tardive dyskinesia.

  1988cited by this paper
• Dopamine receptors and the dopamine hypothesis of schizophrenia

  1987cited by this paper
• Tardive dyskinesia: reversible and irreversible.

  1985influential reference
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983influential reference
• Tardive dyskinesia: prevalence and risk factors, 1959 to 1979

  1982cited by this paper
• Tardive dyskinesia--reversible and persistent.

  1979influential reference
• The pathophysiologic basis of tardive dyskinesia.

  1977cited by this paper
• Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

  1977cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

  1976cited by this paper
• Persistent Dyskinesia

  1973influential reference
• Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature.

  1968cited by this paper

• Effects of Acute Haloperidol Treatment on Dopaminergic Markers, GAD67, and A2A Receptors in Rats with High and Low VCMs

  2024cites this paper
• Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats

  2023cites this paper
• Associations between polymorphisms in the cannabinoid receptor 1 gene, cognitive impairments and tardive dyskinesia in a Chinese population with schizophrenia.

  2023cites this paper
• Cannabinoid-Based Medicine: Pharmacology and Drug Interactions

  2022cites this paper
• Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats

  2022cites this paper
• Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist–induced orofacial dyskinesia

  2021cites this paper
• Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.

  2021cites this paper
• Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol

  2020cites this paper
• Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans

  2020cites this paper
• A review for the pharmacological effect of lycopene in central nervous system disorders.

  2019cites this paper
• Gabapentin reduces haloperidol‐induced vacuous chewing movements in mice

  2018cites this paper
• Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine

  2017cites this paper
• Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain

  2016cites this paper
• Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.

  2016cites this paper